Lenacapavir is a revolutionary long-acting injectable drug that offers six months of protection with just two annual ...

South Africa's Health Product Regulatory Authority (SAHPRA) has approved the use of the twice-yearly HIV prevention drug, lenacapavir. In a statement released on 27 October, the regulatory body said ...

South Africa has become the first African country to register lenacapavir, a groundbreaking six-monthly HIV prevention ...

The drug, Lenacapavir, is the world's first injectable Pre-Exposure Prophylaxis (PrEP). According to the World Health ...

South Africa’s Health Product Regulatory Authority (SAHPRA) has approved the use of the twice-yearly HIV prevention drug, lenacapavir. In a statement released on 27 October, the regulatory body said ...

The South African Health Products Regulatory Authority has approved Lenacapavir, a long-acting injection that prevents HIV ...

South Africa has become the first African country, and our medicines regulator the third worldwide, to register the ...

South Africa has become the first African country – and our medicines regulator the third worldwide – to register the ...

The South African Health Products Regulatory Authority (SAHPRA) has announced the registration of lenacapavir, making South ...

An HIV prevention jab that provides six months of protection at a time was given the green light by South Africa's medicines regulator. The approval helps to clear the way for a limited public sector ...

The drug can be produced for as little as $25 per person annually, but even at $2000 per person, it can reduce new US infections almost entirely, a researcher says.

Dr Joel Steingo of TB HIV Care says Lenacapavir could be a breakthrough in reducing infections, especially at a time when ...